Peak sales target
Search documents
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch (NASDAQ:BCAB)
Seeking Alpha· 2025-11-13 23:52
Group 1 - The article does not provide any relevant content regarding company or industry insights [1]
